Evidence map›Paper›PMID 29801480›Full record

ArticleBMC cancer2018

IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.

Carrie D House, Valentina Grajales, Michelle Ozaki, Elizabeth Jordan, Helmae Wubneh, Danielle C Kimble, Jana M James, Marianne K Kim, Christina M Annunziata

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Silencing IKBKE inhibits the migration and invasion of glioblastoma by promoting Snail1 degradation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Carrie D HouseWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Valentina GrajalesWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Michelle OzakiWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Elizabeth JordanWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Helmae WubnehWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Danielle C KimbleWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Jana M JamesWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Marianne K KimWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Christina M AnnunziataWomen's Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. annunzic@mail.nih.gov.ORCID http://orcid.org/0000-0003-2033-6532
National Cancer Institute · US

Funding

Nuclear Factor-kappaB in Ovarian CancerZIABC011054 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ANNUNZIATA, CHRISTINA · 2009 to 2023
$12.1M
Role of NF-kB signaling in supporting ovarian cancer tumor-initiating cells responsible for cancer recurrenceR00CA204727 · NCI · SAN DIEGO STATE UNIVERSITY · PI HOUSE, CARRIE DANIELLE · 2018 to 2020
$861k
Intramural NIH HHS ZIA BC011054NCI NIH HHS K99 CA204727NCI NIH HHS R00 CA204727NCI NIH HHS ZIA BC 011054
6 · The paper itself

Abstract

backgroundMetastatic breast cancer carries a poor prognosis despite the success of newly targeted therapies. Treatment options remain especially limited for the subtype of triple negative breast cancer (TNBC). Several signaling pathways, including NF-κB, are altered in TNBC, and the complexity of this disease implies multi-faceted pathway interactions. Given that IKKε behaves as an oncogene in breast cancer, we hypothesized that IKKε regulates NF-κB signaling to control diverse oncogenic functions in TNBC.

methodsVector expression and RNA interference were used to investigate the functional role of IKKε in triple-negative breast cancer cells. Viability, protein expression, NF-κB binding activity, invasion, anoikis, and spheroid formation were examined in cells expressing high or low levels of IKKε, in conjunction with p52 RNA interference or MEK inhibition.

resultsThis study found that non-canonical NF-κB p52 levels are inversely proportional to ΙΚΚε, and growth of TNBC cells in anchorage supportive, high-attachment conditions requires IKKε and activated MEK. Growth of these cells in anchorage resistant conditions requires IKKε and activated MEK or p52. In this model, IKKε and MEK cooperate to support overall viability whereas the p52 transcription factor is only required for viability in low attachment conditions, underscoring the contrasting roles of these proteins.

conclusionsThis study illustrates the diverse functions of IKKε in TNBC and highlights the adaptability of NF-κB signaling in maintaining cancer cell survival under different growth conditions. A better understanding of the diversity of NF-κB signaling may ultimately improve the development of novel therapeutic regimens for TNBC.

Indexed as

Gene Expression Regulation, NeoplasticCarcinogenesisCell Line, TumorCell ProliferationCell SurvivalFemaleHumansI-kappa B KinaseMitogen-Activated Protein Kinase KinasesNF-kappa B p52 SubunitRNA InterferenceRNA, Small InterferingSignal TransductionTriple Negative Breast NeoplasmsI-kappa B KinaseIKBKE protein, humanMitogen-Activated Protein Kinase KinasesNF-kappa B p52 SubunitNFKB2 protein, humanRNA, Small InterferingAnoikisIKK-epsilonNF-kappaBNon-canonical signalingTriple negative breast cancer

Identifiers

PMID29801480
PMCPMC5970439
OpenAlexW2806528372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.